Pierre Legault's most recent trade in Syndax Pharmaceuticals Inc was a trade of 24,000 Common Stock done . Disclosure was reported to the exchange on Feb. 4, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Syndax Pharma Inc | Pierre Legault | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2026 | 24,000 | 114,000 (0%) | 0% | 0 | Common Stock | |
| Syndax Pharma Inc | Pierre Legault | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2025 | 25,000 | 90,000 (0%) | 0% | 0 | Common Stock | |
| Bicycle Therapeutics PLC (ADR) | Pierre Legault | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Bicycle Therapeutics PLC (ADR) | Pierre Legault | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 12,500 | 46,000 | - | 0 | Ordinary Shares | |
| Syndax Pharma Inc | Pierre Legault | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2024 | 17,000 | 65,000 (0%) | 0% | 0 | Common Stock | |
| Bicycle Therapeutics PLC (ADR) | Pierre Legault | Director | 02 Jan 2024 | 24,000 | 24,000 | - | - | Stock Option (right to buy) | ||
| Bicycle Therapeutics PLC (ADR) | Pierre Legault | Director | 02 Jan 2024 | 12,000 | 33,500 | - | 0 | Ordinary Shares | ||
| Syndax Pharma Inc | Pierre Legault | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2023 | 16,000 | 48,000 (0%) | 0% | 0 | Common Stock | |
| Syndax Pharma Inc | Pierre Legault | Director | Sale of securities on an exchange or to another person at price $ 26.74 per share. | 12 Jan 2023 | 24,000 | 32,000 (0%) | 0% | 26.7 | 641,782 | Common Stock |
| Syndax Pharma Inc | Pierre Legault | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jan 2023 | 24,000 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharma Inc | Pierre Legault | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.47 per share. | 12 Jan 2023 | 24,000 | 56,000 (0%) | 0% | 9.5 | 227,280 | Common Stock |
| Syndax Pharma Inc | Pierre Legault | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jan 2023 | 10,000 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharma Inc | Pierre Legault | Director | Sale of securities on an exchange or to another person at price $ 27.00 per share. | 12 Jan 2023 | 10,000 | 32,000 (0%) | 0% | 27 | 270,000 | Common Stock |
| Syndax Pharma Inc | Pierre Legault | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.58 per share. | 12 Jan 2023 | 10,000 | 42,000 (0%) | 0% | 13.6 | 135,800 | Common Stock |
| Syndax Pharma Inc | Pierre Legault | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jan 2023 | 5,000 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharma Inc | Pierre Legault | Director | Sale of securities on an exchange or to another person at price $ 27.00 per share. | 12 Jan 2023 | 5,000 | 32,000 (0%) | 0% | 27 | 135,000 | Common Stock |
| Syndax Pharma Inc | Pierre Legault | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.58 per share. | 12 Jan 2023 | 5,000 | 37,000 (0%) | 0% | 13.6 | 67,900 | Common Stock |
| Syndax Pharma Inc | Pierre Legault | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2022 | 14,000 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharma Inc | Pierre Legault | Director | Sale of securities on an exchange or to another person at price $ 23.02 per share. | 05 Aug 2022 | 14,000 | 32,000 (0%) | 0% | 23.0 | 322,223 | Common Stock |
| Syndax Pharma Inc | Pierre Legault | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.93 per share. | 05 Aug 2022 | 14,000 | 46,000 (0%) | 0% | 8.9 | 125,020 | Common Stock |
| Syndax Pharma Inc | Pierre Legault | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.63 per share. | 05 Aug 2022 | 10,000 | 42,000 (0%) | 0% | 9.6 | 96,300 | Common Stock |
| Syndax Pharma Inc | Pierre Legault | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2022 | 10,000 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharma Inc | Pierre Legault | Director | Sale of securities on an exchange or to another person at price $ 23.02 per share. | 05 Aug 2022 | 10,000 | 32,000 (0%) | 0% | 23.0 | 230,159 | Common Stock |
| Syndax Pharma Inc | Pierre Legault | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2022 | 16,000 | 32,000 (0%) | 0% | 0 | Common Stock | |
| Syndax Pharma Inc | Pierre Legault | Director | Sale of securities on an exchange or to another person at price $ 22.01 per share. | 20 Dec 2021 | 24,000 | 16,000 (0%) | 0% | 22.0 | 528,206 | Common Stock |
| Syndax Pharma Inc | Pierre Legault | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.88 per share. | 20 Dec 2021 | 24,000 | 40,000 (0%) | 0% | 7.9 | 189,120 | Common Stock |
| Syndax Pharma Inc | Pierre Legault | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Dec 2021 | 24,000 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharma Inc | Pierre Legault | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Dec 2021 | 20,000 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharma Inc | Pierre Legault | Director | Sale of securities on an exchange or to another person at price $ 21.01 per share. | 20 Dec 2021 | 20,000 | 16,000 (0%) | 0% | 21.0 | 420,250 | Common Stock |
| Syndax Pharma Inc | Pierre Legault | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.08 per share. | 20 Dec 2021 | 20,000 | 36,000 (0%) | 0% | 7.1 | 141,600 | Common Stock |